Education
About Us
Working with TipRanks
Follow Us
Pacira Pharmaceuticals (PCRX)
NASDAQ:PCRX
Top Page
Pacira Pharmaceuticals
(NASDAQ:PCRX)
Select Model
Select Model
Rating:69Neutral
Price Target:
$26.00
▼(-0.08% Downside)
Pacira Pharmaceuticals' overall stock score is driven by its stable financial performance and positive earnings call highlights, including strong revenue growth and strategic initiatives. However, the stock's high valuation and technical indicators suggest caution, as it appears overvalued and shows signs of weak momentum.
Positive Factors
Revenue Growth
Consistent revenue growth, particularly from core products like EXPAREL, indicates strong market demand and positions Pacira for continued expansion.
Pipeline Expansion
Expanding the product pipeline with innovative formulations like AMT-143 enhances long-term growth prospects and strengthens competitive positioning.
Cash Flow and Shareholder Returns
Strong cash flow and strategic share repurchases reflect financial health and commitment to shareholder value, supporting sustainable growth.
Negative Factors
Zilretta Sales
Sluggish sales of Zilretta indicate challenges in market penetration and could impact overall revenue growth if not addressed.
GPO Discount Impact
Higher-than-expected discounting pressures from GPO agreements may compress margins, affecting profitability and pricing strategy.
Elective Procedure Market
Sluggish growth in elective procedures could limit demand for Pacira's products, impacting revenue potential in a key market segment.
Pacira Pharmaceuticals (PCRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.12B
Dividend YieldN/A
Average Volume (3M)564.80K
Price to Earnings (P/E)58.3
Beta (1Y)0.82
Revenue Growth3.14%
EPS GrowthN/A
CountryUS
Employees788
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.70
Shares Outstanding43,021,275
10 Day Avg. Volume629,963
30 Day Avg. Volume564,800
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.12
Price to Sales (P/S)1.24
P/FCF Ratio4.87
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$29.71Price Target Upside14.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Pacira Pharmaceuticals Business Overview & Revenue Model
Company DescriptionPacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
How the Company Makes MoneyPacira Pharmaceuticals generates revenue primarily through the sales of its flagship product, EXPAREL, which is marketed to hospitals, surgical centers, and healthcare providers. The company also earns revenue from collaborations and partnerships with other pharmaceutical firms, which may include licensing agreements or co-development arrangements for its pipeline products. Additionally, Pacira may benefit from government reimbursements and healthcare insurance payments for its products, which are crucial for driving sales and expanding market access. The company has strategically focused on building relationships with healthcare professionals and institutions to promote the adoption of non-opioid pain management solutions, contributing to its overall revenue growth.
Pacira Pharmaceuticals Earnings Call Summary
Earnings Call Date:Nov 06, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Feb 19, 2026
Earnings Call Sentiment Positive
The earnings call highlighted strong revenue growth, improved manufacturing efficiencies, and significant pipeline expansion. However, some challenges were noted with Zilretta's slower-than-expected sales growth and discount impacts from new GPO agreements affecting pricing. Elective procedure market growth was also described as sluggish.Q3-2025 Updates
Positive Updates
Revenue Growth
Year-over-year revenues increased by 6%, driven by strong performance from EXPAREL and iovera. EXPAREL demand increased with year-over-year volumes up approximately 9%, marking the highest quarterly growth in over 3 years.
Manufacturing and Gross Margin
Improved manufacturing efficiencies and gross margins supported an increase in full-year guidance. Non-GAAP gross margins improved to 82% in the third quarter from 78% last year.
Pipeline Expansion
Clinical pipeline expanded with the in-licensing of AMT-143, a novel long-acting formulation of bupivacaine. The company also reported progress in its Phase II study of PCRX-201 for osteoarthritis of the knee.
Market Access and Coverage
The company is ahead of plan to surpass the full-year goal of 100 million covered lives across commercial and government payers. Approximately 60 million commercial lives now have access to EXPAREL via separate reimbursement.
Cash Flow and Shareholder Returns
Significant operating cash flow and a strong balance sheet enable investments in new growth initiatives. The company executed an additional $50 million in share repurchases during the quarter.
Negative Updates
Zilretta Sales
Zilretta sales were slower than anticipated, with only a slight increase to $29.0 million from $28.4 million in 2024.
GPO Discount Impact
Discounting from the third GPO agreement resulted in a higher-than-expected single-digit year-over-year impact on net selling prices.
Elective Procedure Market
Elective procedures were sluggish in the first half of the year, and while there were modest improvements in the third quarter, the growth was not monumental.
Company Guidance
During the Pacira BioSciences third quarter 2025 earnings call, the company provided several key performance metrics and guidance. Year-over-year revenues increased by 6%, driven by a 9% rise in EXPAREL demand, marking the highest quarterly growth in over three years. The company reported EXPAREL sales of $139.9 million, Zilretta sales of $29.0 million, and iovera sales of $6.5 million for the third quarter. Non-GAAP gross margins improved to 82%, compared to 78% the previous year, with the guidance for full-year revenues narrowed to $725 million to $735 million. The company also highlighted its strategic initiatives, such as the in-licensing of AMT-143, a novel long-acting formulation of bupivacaine, and emphasized its robust patent protection with the listing of the 21st EXPAREL patent in the FDA's Orange Book. With significant cash flows, a strong balance sheet, and strategic share repurchases totaling $50 million, Pacira BioSciences is well-positioned to advance its 5x30 growth strategy, aiming for a five-year double-digit compound annual growth rate (CAGR) for revenue.Pacira Pharmaceuticals Financial Statement Overview
Summary
Pacira Pharmaceuticals exhibits stable financial health with consistent revenue growth and improved operational efficiency. The company has effectively managed its debt, enhancing its financial stability. Cash flow generation remains strong, supporting future growth opportunities. However, profitability margins could be improved to enhance shareholder value.Income Statement
Pacira Pharmaceuticals shows a modest revenue growth rate of 1.55% TTM, with a stable gross profit margin of 58.9%. However, the net profit margin is relatively low at 4.13%, indicating limited profitability. The EBIT and EBITDA margins have improved over the previous year, suggesting better operational efficiency.Balance Sheet
The company has significantly reduced its debt-to-equity ratio to 0.013 TTM, indicating strong financial stability. The return on equity is modest at 3.87%, reflecting moderate profitability. The equity ratio is healthy, showing a solid capital structure.Cash Flow
Pacira Pharmaceuticals has achieved a free cash flow growth rate of 6.1% TTM, demonstrating strong cash generation capabilities. The operating cash flow to net income ratio is robust at 1.32, indicating efficient cash conversion. The free cash flow to net income ratio is also strong at 0.88.| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 716.79M | 700.97M | 674.98M | 666.82M | 541.53M | 429.65M |
| Gross Profit | 567.46M | 530.54M | 490.31M | 467.53M | 401.28M | 312.32M |
| EBITDA | 147.82M | 29.12M | 154.59M | 140.38M | 113.95M | 63.51M |
| Net Income | 21.44M | -99.56M | 41.95M | 15.91M | 41.98M | 145.52M |
Balance Sheet | ||||||
| Total Assets | 1.30B | 1.55B | 1.57B | 1.68B | 2.08B | 1.27B |
| Cash, Cash Equivalents and Short-Term Investments | 246.33M | 484.62M | 278.58M | 288.65M | 656.41M | 521.66M |
| Total Debt | 425.31M | 638.85M | 586.04M | 763.39M | 1.13B | 541.13M |
| Total Liabilities | 570.36M | 775.17M | 704.26M | 906.19M | 1.34B | 654.83M |
| Stockholders Equity | 727.21M | 778.35M | 870.13M | 775.01M | 730.41M | 619.69M |
Cash Flow | ||||||
| Free Cash Flow | 124.20M | 178.75M | 139.49M | 115.20M | 79.85M | 39.23M |
| Operating Cash Flow | 141.44M | 189.39M | 154.65M | 145.27M | 125.72M | 77.03M |
| Investing Cash Flow | 79.78M | -83.28M | 77.54M | -225.19M | -20.79M | -277.61M |
| Financing Cash Flow | -319.93M | 17.36M | -183.03M | -401.53M | 380.69M | 222.30M |
Pacira Pharmaceuticals Technical Analysis
Positive
26.02
Price Trends
24.25
Positive
24.61
Positive
24.54
Positive
Market Momentum
0.33
Positive
56.38
Neutral
60.41
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PCRX, the sentiment is Positive. The current price of 26.02 is above the 20-day moving average (MA) of 25.90, above the 50-day MA of 24.25, and above the 200-day MA of 24.54, indicating a bullish trend. The MACD of 0.33 indicates Positive momentum. The RSI at 56.38 is Neutral, neither overbought nor oversold. The STOCH value of 60.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PCRX.
Pacira Pharmaceuticals Risk Analysis
Pacira Pharmaceuticals disclosed 69 risk factors in its most recent earnings report. Pacira Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Pacira Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | $1.27B | 12.30 | 14.84% | ― | -0.03% | -27.66% | |
72 Outperform | $1.54B | 30.36 | 22.96% | ― | 26.34% | -32.79% | |
69 Neutral | $1.12B | 58.33 | 2.90% | ― | 3.14% | ― | |
64 Neutral | $1.71B | 49.70 | 7.83% | ― | 48.87% | ― | |
58 Neutral | $2.10B | -3,905.45 | -0.32% | ― | 79.88% | 99.60% | |
55 Neutral | $2.93B | -150.15 | -1.86% | ― | 4.54% | -130.59% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
PCRX
Pacira Pharmaceuticals
26.02
4.89
23.14%
AVDL
Avadel Pharmaceuticals
21.48
13.66
174.68%
SUPN
Supernus Pharmaceuticals
51.17
13.60
36.20%
ANIP
ANI Pharmaceuticals
81.04
27.11
50.27%
AMPH
Amphastar Pharmaceuticals
27.74
-10.18
-26.85%
COLL
Collegium Pharmaceutical
48.78
14.99
44.36%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.